T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2024
0mins
Milestone Achievement: T2 Biosystems has surpassed 250,000 shipments of its sepsis tests, indicating increased adoption of its direct-from-whole-blood technology.
Study Findings: A meta-analysis and a new prospective study published in medical journals demonstrate that T2 Biosystems' tests offer faster detection, targeted therapy, and improved clinical outcomes compared to traditional blood culture methods.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
